Clinical Impact of β-Lactamase-producing Enterobacteriaceae in Sputum of Cystic Fibrosis Patients

Pediatr Infect Dis J. 2016 Feb;35(2):216-9. doi: 10.1097/INF.0000000000000972.

Abstract

This case series describes 18 cystic fibrosis (CF) patients of a 135-patient CF center cohort with extended spectrum β-lactamase-producing Enterobacteriaceae, from 2003 to 2012. Four had chronic infection. Prevalence increased annually from 0 to 6.35%. Risk factors compared with the 2010 CF center cohort included continuous inhaled antibiotics (P = 0.014) and courses of intravenous antibiotics during the year before first isolation (P = 0.009). Hospitalization rates were 1.05/year and 0.47/year preinfection and postinfection, respectively (P = 0.02). Slope of forced expiratory volume at 1 second% predicted remained unchanged during 12 months.

MeSH terms

  • Adolescent
  • Adult
  • Carrier State / microbiology
  • Child
  • Child, Preschool
  • Cohort Studies
  • Cystic Fibrosis / complications
  • Cystic Fibrosis / microbiology*
  • Enterobacteriaceae / enzymology*
  • Enterobacteriaceae / isolation & purification*
  • Enterobacteriaceae Infections / epidemiology
  • Enterobacteriaceae Infections / microbiology*
  • Female
  • Hospitalization
  • Humans
  • Infant
  • Israel / epidemiology
  • Male
  • Middle Aged
  • Prevalence
  • Sputum / microbiology*
  • Young Adult
  • beta-Lactamases / metabolism*

Substances

  • beta-Lactamases